Efficacy of alectinib as subsequent treatments was reported by phase II trials with a total response rate of 48% to 50% in metastatic NSCLC patients with ALK rearrangement progressing after crizotinib treatment (55, 56). This evidence concerns the gene ALK and non-small cell lung carcinoma.